JP7898188B2 - 免疫原性化合物 - Google Patents
免疫原性化合物Info
- Publication number
- JP7898188B2 JP7898188B2 JP2023507480A JP2023507480A JP7898188B2 JP 7898188 B2 JP7898188 B2 JP 7898188B2 JP 2023507480 A JP2023507480 A JP 2023507480A JP 2023507480 A JP2023507480 A JP 2023507480A JP 7898188 B2 JP7898188 B2 JP 7898188B2
- Authority
- JP
- Japan
- Prior art keywords
- asyn
- disease
- peptide
- amino acid
- dementia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Psychiatry (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20189425 | 2020-08-04 | ||
| EP20189425.0 | 2020-08-04 | ||
| PCT/EP2021/071778 WO2022029181A1 (en) | 2020-08-04 | 2021-08-04 | Immunogenic compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023536497A JP2023536497A (ja) | 2023-08-25 |
| JP2023536497A5 JP2023536497A5 (cg-RX-API-DMAC7.html) | 2024-08-13 |
| JP7898188B2 true JP7898188B2 (ja) | 2026-07-31 |
Family
ID=72178339
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023507480A Active JP7898188B2 (ja) | 2020-08-04 | 2021-08-04 | 免疫原性化合物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230287050A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4192493A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7898188B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230044524A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116261464A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021322080A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3185563A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL300364A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023001483A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022029181A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL314865A (en) * | 2022-02-09 | 2024-10-01 | Ac Immune Sa | Anti-alpha-synuclein therapeutic vaccines |
| KR20250135293A (ko) | 2023-01-26 | 2025-09-12 | 에이씨 이뮨 에스에이 | 리포좀 구조체 |
| WO2025109524A1 (en) | 2023-11-22 | 2025-05-30 | Ac Immune Sa | Assays and methods for assessing vaccine preparations |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014528695A (ja) | 2011-06-23 | 2014-10-30 | バイオジェン アイデック インターナショナル ニューロサイエンス ゲーエムベーハー | 抗アルファシヌクレイン結合分子 |
| JP2016216482A (ja) | 2008-02-22 | 2016-12-22 | アフィリス・アクチェンゲゼルシャフトAffiris Ag | 神経変性疾患治療のためのαシヌクレインのミモトープ及びそれらのワクチン |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2361928T3 (en) | 2003-05-19 | 2017-07-03 | Prothena Biosciences Ltd | Truncated fragments of alpha synuclein in Lewy body disease |
| US20050203010A1 (en) | 2003-11-14 | 2005-09-15 | Atgen Co., Ltd. | Novel peptides conferring environmental stress resistance and fusion proteins including said peptides |
| AT508638B1 (de) | 2009-08-21 | 2011-08-15 | Affiris Ag | Verwendung von peptiden und polypeptiden zur behandlung und/oder prävention von synukleinopathien |
| CA3003943A1 (en) | 2015-11-03 | 2017-05-11 | Affiris Ag | Method for vaccination against a self-antigen in a human patient |
| JP7136790B2 (ja) * | 2017-02-17 | 2022-09-13 | ブリストル-マイヤーズ スクイブ カンパニー | アルファ-シヌクレインに対する抗体およびその使用 |
| JP2021508672A (ja) * | 2017-06-16 | 2021-03-11 | ユナイテッド ニューロサイエンスUnited Neuroscience | シヌクレイノパチーの治療のためのアルファ−シヌクレインタンパク質のc末端からのペプチド免疫原及びその製剤 |
| WO2021055881A1 (en) * | 2019-09-20 | 2021-03-25 | Denali Therapeutics Inc. | Anti-alpha-synuclein antibodies and methods of use thereof |
-
2021
- 2021-08-04 JP JP2023507480A patent/JP7898188B2/ja active Active
- 2021-08-04 MX MX2023001483A patent/MX2023001483A/es unknown
- 2021-08-04 AU AU2021322080A patent/AU2021322080A1/en active Pending
- 2021-08-04 KR KR1020237007745A patent/KR20230044524A/ko active Pending
- 2021-08-04 US US18/014,846 patent/US20230287050A1/en active Pending
- 2021-08-04 CA CA3185563A patent/CA3185563A1/en active Pending
- 2021-08-04 EP EP21758636.1A patent/EP4192493A1/en active Pending
- 2021-08-04 WO PCT/EP2021/071778 patent/WO2022029181A1/en not_active Ceased
- 2021-08-04 IL IL300364A patent/IL300364A/en unknown
- 2021-08-04 CN CN202180050068.9A patent/CN116261464A/zh active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016216482A (ja) | 2008-02-22 | 2016-12-22 | アフィリス・アクチェンゲゼルシャフトAffiris Ag | 神経変性疾患治療のためのαシヌクレインのミモトープ及びそれらのワクチン |
| JP2014528695A (ja) | 2011-06-23 | 2014-10-30 | バイオジェン アイデック インターナショナル ニューロサイエンス ゲーエムベーハー | 抗アルファシヌクレイン結合分子 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116261464A (zh) | 2023-06-13 |
| IL300364A (en) | 2023-04-01 |
| US20230287050A1 (en) | 2023-09-14 |
| WO2022029181A1 (en) | 2022-02-10 |
| CA3185563A1 (en) | 2022-02-10 |
| AU2021322080A1 (en) | 2023-02-23 |
| MX2023001483A (es) | 2023-03-08 |
| KR20230044524A (ko) | 2023-04-04 |
| EP4192493A1 (en) | 2023-06-14 |
| JP2023536497A (ja) | 2023-08-25 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240802 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240802 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20250707 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250715 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20251007 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20251209 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260402 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20260402 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20260630 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20260713 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7898188 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |